Chronic obstructive pulmonary disease
Conditions
Interventions
Staphylococcus and Neisseria Tablets group:Based on the follow-up, the subjects were additionally given Staphylococcus and Neisseria Tablets.
Staphylococcus and Neisseria Tablets (Qilu Pharmaceutical
Staphylococcus and Neisseria Tablets Joint Respiratory Rehabilitation group:The patient is undergoing respiratory rehabilitation training while taking Staphylococcus and Neisseria Tablets.
Staphylococ
Respiratory rehabilitation group:Respiratory Rehabilitation
Simultaneous respiratory rehabilitation training includes aerobic exercise, respiratory muscle training, and so on.
Control group:None
Sponsors
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: Participants are aged between 45 and 80 years, with no restrictions on ethnicity or gender; 2: Participants agree to take part in this study and sign the informed consent form; 3: Participants meet the diagnostic criteria for PRISm; 4: Have no history of asthma, overlap syndrome, chronic infections, parasitic diseases, etc.; 5: Understand the entire trial process, voluntarily participate, and are able to comply with the study protocol during the research period, cooperating to complete various assessments and examinations.
Exclusion criteria
Exclusion criteria: Exclusion criteria: Subjects meeting one or more of the following conditions will be excluded: 1: Subjects with severe respiratory diseases that may affect lung function test results; 2: Women who are pregnant, planning pregnancy, or breastfeeding; 3: Subjects with pneumonia, lung cancer, active tuberculosis, or other lung diseases; 4:Subjects with allergies or who are allergic to the study drug; 5: Subjects with severe hepatic or renal dysfunction, cardiovascular or cerebrovascular diseases, which may affect drug metabolism and efficacy evaluation; 6: Subjects who have participated in other interventional clinical studies within 1 month prior to inclusion; 7: Subjects with psychiatric disorders or cognitive dysfunction who are unable to cooperate to complete the study; 8: Subjects with malignant tumors, autoimmune diseases, or other serious illnesses; 9: Subjects who have used glucocorticoids, leukotriene receptor antagonists, antihistamines, or similar drugs within the past month; 10: Subjects who have had an infection or have been on long-term antibiotics within the past two weeks, or who experience serious adverse drug reactions or complications during the study that require treatment adjustment or early withdrawal from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory marker testing;mMRC questionnaire;CAT score;Lung function test; | — |
Countries
China
Contacts
Public ContactWang Jun
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Outcome results
None listed